Pharmaceuticals

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

A new drug combination delays cancer progression by over a year in advanced prostate cancer, offering new hope against treatment resistance, a new study finds.

New long-term data on pegcetacoplan offers significant hope for patients with rare, debilitating kidney diseases, strengthening Sobi's market position.

Haisco's Cipepofol gains US FDA approval, challenging Propofol with enhanced safety and signaling a new era of Chinese pharmaceutical innovation.

With strong data for volixibat, brelovitug, and LIVMARLI, Mirum (MIRM) de-risks its pipeline and sets the stage for growth. Here's the analysis.

Facing delisting, biotech firm Cuprina Holdings executes a reverse split and appeals to Nasdaq. Will the high-stakes gamble pay off for the company?

A Canadian company's sublingual tablet could replace injections for popular peptides, just as the FDA considers expanding access for millions of users.

Landmark Phase 3 trial shows TECVAYLI dramatically improves survival in early relapse, poised to become a new standard of care for multiple myeloma.

The specialty infusion provider taps veteran Dan Teich for a new SVP role, aiming to streamline partner relations and accelerate its growth to 50+ locations.

Cumberland Pharmaceuticals and SciClone launch Vibativ in China, offering a new defense against deadly, drug-resistant bacteria in a high-stakes market.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.

With Ozempic at generic prices and a new free-to-start model, Felix Health is making high-demand weight-loss drugs more accessible than ever for Canadians.

BeOne Medicines' immunotherapy TEVIMBRA gains key reimbursement nods, paving the way for Canada's first funded option for a rare head and neck cancer.

ZYUS secures high-interest debt to stay afloat, but a trading halt and unresolved accounting issues raise serious questions about its long-term resilience.

A new telehealth platform offers popular weight loss drugs for $149/month, but there's a catch: they aren't FDA-approved. Here's what you need to know.

A new compounding base from PCCA blends peptides, exosomes, and zinc hyaluronate, aiming to redefine customized anti-aging solutions for pharmacists.

Uncommon Productions' 'Cracking the Code' earns top honors, celebrating the biotech revolution and the power of scientific ingenuity.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

Sensorium Therapeutics advances SNTX-2643, a novel anxiety drug, while adding a new CMO and an expert advisory board to guide its clinical journey.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.